Shots:

• The P-II KINETIC study involves assessing the efficacy- safety- and tolerability of SAGE-324 (60mg- qd) vs PBO in 69 patients in a ratio (1:1) aged 18-80yrs. with essential tremor for 29 days
• The study met its 1EPs i.e reduction from baseline in TETRAS Performance Subscale Item 4 upper limb tremor score @29day (36% vs 21%)- ADL score is numerically superior at all time points- consistent safety profile with previously reported data
• In a more severe population- a reduction from baseline in tetras Upper Limb Item 4 >12- SAGE-32 demonstrated a (41% vs 18%) reduction from baseline in upper limb tremor amplitude

  Ref: Businesswire | Image: Biogen